Tyr664
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr664  -  NPM-ALK (human)

Site Information
TAPGAGHyEDTILKS   GenPept
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 27275123
Available spectra:  3 CST
Associated spectra:  3 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 , 3 , 4 , 5 ) , microscopy-colocalization with upstream kinase ( 8 ) , mutation of modification site ( 6 , 7 ) , phospho-antibody ( 1 , 6 , 8 ) , western blotting ( 1 , 6 )
Disease tissue studied:
non-small cell lung cancer ( 2 ) , non-small cell lung adenocarcinoma ( 2 ) , lymphoma ( 6 , 8 ) , anaplastic large cell lymphoma ( 6 ) , T cell lymphoma ( 6 , 8 ) , neuroblastoma ( 4 )
Relevant cell line - cell type - tissue:
293GP (epithelial) ( 3 , 5 ) , 3T3 (fibroblast) ( 6 , 8 ) , BaF3 ('B lymphocyte, precursor') ( 6 ) , HEK293T (epithelial) ( 1 ) , Jurkat (T lymphocyte) ( 7 ) , Karpas-299 (T lymphocyte) ( 6 , 8 ) , lymphocyte-blood ( 6 ) , NCI-H2228 (pulmonary) ( 2 ) , SH-SY5Y (neural crest) ( 4 )

Upstream Regulation
Putative upstream phosphatases:
SHP-1 (human) ( 8 )
Treatments:
LY294002 ( 6 ) , SU6656 ( 6 ) , WHI-P154 ( 6 )

Downstream Regulation
Effects of modification on biological processes:
cell growth, induced ( 8 ) , transcription, induced ( 7 )

References 

1

Lovisa F, et al. (2015) ALK Kinase Domain Mutations in Primary Anaplastic Large Cell Lymphoma: Consequences on NPM-ALK Activity and Sensitivity to Tyrosine Kinase Inhibitors. PLoS One 10, e0121378
25874976   Curated Info

2

Rikova K (2013) CST Curation Set: 18449; Year: 2012; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) MultiMab(TM) Rabbit mAb mix Cat#: 8954
Curated Info

3

Wang P, et al. (2011) Serine phosphorylation of NPM-ALK, which is dependent on the auto-activation of the kinase activation loop, contributes to its oncogenic potential. Carcinogenesis 32, 146-53
21045017   Curated Info

4

Guo A (2010) CST Curation Set: 10556; Year: 2010; Biosample/Treatment: cell line, SH-SY5Y/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

5

Wang P, et al. (2010) Functional characterization of the kinase activation loop in nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) using tandem affinity purification and liquid chromatography-mass spectrometry. J Biol Chem 285, 95-103
19887368   Curated Info

6

Colomba A, et al. (2008) Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas. Oncogene 27, 2728-36
17998938   Curated Info

7

Turner SD, et al. (2007) The NPM-ALK tyrosine kinase mimics TCR signalling pathways, inducing NFAT and AP-1 by RAS-dependent mechanisms. Cell Signal 19, 740-7
17110082   Curated Info

8

Honorat JF, et al. (2006) SHP1 tyrosine phosphatase negatively regulates NPM-ALK tyrosine kinase signaling. Blood 107, 4130-8
16469875   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.